Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 15/20 | 0.69 |
| ▸ | SRC | P12931 | 10/20 | 0.69 |
| ▸ | EGFR | P00533 | 9/20 | 0.69 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.69 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.69 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.66 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.66 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.66 |
| ▸ | WEE1 | P30291 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 6/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.59 |
| ▸ | KIT | P10721 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498171 | 1.00 | FGFR1 (0.69) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL4083936 | 0.89 | RIPK2 (0.65) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL20564935 | 0.88 | RIPK2 (0.66) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL29498190 | 0.88 | RIPK2 (0.66) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL5763667 | 0.85 | FGFR1 (0.63) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL25399083 | 0.84 | FGFR1 (0.77) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL29498209 | 0.83 | RIPK2 (0.64) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL20563498 | 0.83 | RIPK2 (0.64) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL20563987 | 0.83 | RIPK2 (0.56) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL29498241 | 0.83 | RIPK2 (0.56) | FGFR1SRCEGFRFGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | claimed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | claimed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | claimed |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2026-05-12 | — | — | US | disclosed |
| US-12516055-B2 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions | TRUSTEES OF TUFTS COLLEGE (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4480485-A2 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | University of Houston System (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240327403-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3968991-B1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | UNIV HOUSTON SYSTEM (US) | 2024-07-31 | — | — | EP | disclosed |
| US-12012402-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-06-18 | — | — | US | disclosed |
| WO-2023177356-A2 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023177356-A2 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-09-21 | — | — | WO | disclosed |
| WO-2007080324-A2 | PYRIDOPYRIMIDONE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF | SANOFIS-AVENTIS (FR) | 2007-07-19 | — | — | WO | disclosed |
| EP-1734367-A1 | Process for the identification of novel enzyme interacting compounds | CELLZOME AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | disclosed |
| US-20050009849-A1 | Pyridopyrimidine kinase inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2005-01-13 | — | — | US | disclosed |
| WO-2004063195-A1 | PYRIDOPYRIMIDINE KINASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009849-A1 | Pyridopyrimidine kinase inhibitors | MAP3K1, MAP3K19, MAP3K20 | FGFR1 192/4885SRC 335/4885EGFR 185/4885 |
| US-20240327403-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | RIPK2, RIPK1, RIPK4 | FGFR1 534/4885SRC 2385/4885EGFR 1321/4885 |
| US-12012402-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | FGFR1 534/4885SRC 2385/4885EGFR 1321/4885 |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | FGFR1 996/4885SRC 994/4885EGFR 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.